Premature coronary artery disease in Indians and its associated risk factors

M Sharma, NK Ganguly - Vascular health and risk management, 2005 - Taylor & Francis
Of particular concern to India is not only the high burden of cardiovascular diseases (CVDs),
but also the effects of these diseases on the productive workforce aged 35–65 years. Heart …

Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future

F Baldanti, NK Ganguly, G Wang… - Critical Reviews in …, 2022 - Taylor & Francis
A plethora of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic
tests are available, each with different performance specifications, detection methods, and …

Health innovation networks to help developing countries address neglected diseases

…, T Acharya, D Broun, A Dangi, C Elias, NK Ganguly… - science, 2005 - science.org
Gross inequities in disease burden between developed and developing countries are now
the subject of intense global attention. Public and private donors have marshaled resources …

Hepatitis E virus transmission to a volunteer

…, YK Chawla, S Jameel, U Kaur, NK Ganguly - The Lancet, 1993 - Elsevier
Hepatitis E virus (HEV) causes an enteric non-A, non-B hepatitis. The disease occurs in
epidemic settings and sporadically, and viral transmission is thought to be faecal-oral. We …

Rheumatoid arthritis: advances in treatment strategies

P Prasad, S Verma, Surbhi, NK Ganguly… - Molecular and cellular …, 2023 - Springer
Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened
autoimmune response at the articular sites. Worldwide annual incidence and prevalence …

[HTML][HTML] Cholera toxin: a paradigm of a multifunctional protein

K Bharati, NK Ganguly - Indian Journal of Medical Research, 2011 - journals.lww.com
Cholera toxin (CT) was discovered exactly half a century ago by SN De. We have come a
long way since this epoch-making discovery. Retrospectively, science had to wait a long time …

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

…, G Anders, H Sindermann, NK Ganguly - The Journal of …, 2007 - academic.oup.com
Background. Visceral leishmaniasis (VL) is a major public health problem in Bihar, accounting
for 90% of all cases in India. Development of high levels of resistance to various existing …

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

…, R Carbis, R Rao, NT Van, A Donner, NK Ganguly… - The Lancet, 2009 - thelancet.com
Background Oral cholera vaccines consisting of killed whole cells have been available for
many years, but they have not been used extensively in populations with endemic disease. An …

Current status of Takayasu arteritis in India

S Jain, S Kumari, NK Ganguly, BK Sharma - International Journal of …, 1996 - Elsevier
The clinical features of 106 patients of Takayasu arteritis (TA) seen over a period of 16
years are documented (65 females and 41 males). The mean age was 27.3 ± 9.2 years. …

[HTML][HTML] A cluster-randomized effectiveness trial of Vi typhoid vaccine in India

…, SK Bhattacharya, NK Ganguly… - … England Journal of …, 2009 - Mass Medical Soc
Background Typhoid fever remains an important cause of illness and death in the developing
world. Uncertainties about the protective effect of Vi polysaccharide vaccine in children …